Lensar (LNSR) Free Cash Flow Growth (1y) (2020 - 2026)
Lensar (LNSR) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | -14.34% |
| 10 | Lensar | 101.76 Mn | 88.19 Mn | 9.78 Mn | 97.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.50% |
| Mar 31, 2026 | 38.49% |
| Dec 31, 2025 | -83.09% |
| Sep 30, 2025 | -212.13% |
| Jun 30, 2025 | -33.38% |
| Mar 31, 2025 | -28.28% |
| Dec 31, 2024 | 796.00% |
| Sep 30, 2024 | 1,018.77% |
| Jun 30, 2024 | -63.66% |
| Mar 31, 2024 | 19.26% |
| Dec 31, 2023 | 89.10% |
| Sep 30, 2023 | 92.75% |
| Jun 30, 2023 | 16.96% |
| Mar 31, 2023 | -152.70% |
| Dec 31, 2022 | -437.99% |
| Sep 30, 2022 | -104.83% |
| Jun 30, 2022 | -100.14% |
| Mar 31, 2022 | 43.95% |
| Dec 31, 2021 | 57.42% |
| Sep 30, 2021 | -3,663.93% |